|
Session 108
Poster Abstracts
Predicting Virologic Response to Pis
Wednesday, 1 - 4 pm
Poster Hall |
| 607 |
Darunavir/Amprenavir Cross-resistance in Clinical Samples Submitted for Phenotype/Genotype Combination Resistance Testing
Neil Parkin*, E Stawiski, C Chappey, and E Coakley
Monogram Biosci, South San Francisco, CA, US |
608
 |
Genotypic Analysis of the Virological Response to Fosamprenavir/Ritonavir in Clinical Trials: Context and Triad
A G Marcelin1, P Flandre1, J M Molina2, C Katlama1, P Yéni3, F Raffi4, M Wirden1, Z Antoun5, M Ait Khaled6, Vincent Calvez*1, and CONTEXT and TRIAD study group
1Ctr Hosp Univ Pitie-Salpetriere, Paris, France; 2Ctr Hosp Univ St Louis, Paris, France; 3Ctr Hosp Univ Bichat, Paris, France; 4Ctr Hosp Univ Nantes, France; 5GlaxoSmithKline, France; and 6GlaxoSmithKline, UK |
| 609 |
Prior Utilization or Resistance to Amprenavir at Screening Has Minimal Effect on the 48-Week Response to Darunavir/r in the POWER 1, 2, and 3 Studies
Gaston Picchio*1, T Vangeneugden2, B Van Baelen2, E Lefebvre1, D Miralles2, and M de Bethune2
1Tibotec Inc, Yardley, PA, US and 2Tibotec BVBA, Mechelen, Belgium |
| 610 |
Defining the Upper and Lower Phenotypic Clinical Cut-offs for Darunavir/Ritonavir by the PhenoSense Assay
Eoin Coakley*1, C Chappey1, J Benhamida1, G Picchio2, and M P de Béthune3
1Monogram Biosci, South San Francisco, CA, US; 2Tibotec Inc, Yardley, PA, US; and 3Tibotec BVBA, Mechelen, Belgium |
| 611 |
Development of VircoTYPE HIV-1 Resistance Analysis including Clinical Cutoffs for Ritonavir-boosted Atazanavir and Fosamprenavir
Bart Winters*1, J Montaner2, R Harrigan2, I Pellegrin3, M Tisdale4, D Seekins5, D Butcher5, J Villacian1, E Van Craenenbroeck1, and L Bacheler6
1Virco BVBA, Mechelen, Belgium; 2BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada; 3Ctr Hosp Univ de Bordeaux, Univ Victor Segalen, France; 4GlaxoSmithKline, Stevenage, UK; 5Bristol-Myers Squibb, Plainsboro, NJ, US; and 6VircoLab, Inc, Durham NC, US |
| 612 |
Mutations Associated with Response to Boosted Tipranavir in HIV-1-infected PI-experienced Patients
A G Marcelin1, B Masquelier2, D Descamps3, J Izopet4, C Charpentier5, C Alloui6, G Peytavin3, M Lavignon7, P Flandre1, Vincent Calvez*1, and TPV ANRS study group
1Ctr Hosp Univ Pitie-Salpetriere, Paris, France; 2Ctr Hosp Univ Bordeaux, France; 3Ctr Hosp Univ Bichat, Paris, France; 4Ctr Hosp Univ Toulouse, France; 5Ctr Hosp Univ Georges Pompidou, Paris, France; 6Ctr Hosp Univ Avicennes, France; and 7Boehringer Ingelheim, France |
613
|
Response to Kaletra-based Second-line Drug Regimen in HIV-1 Patients in Nigeria
Gerald Onwuegbuzie*1, J Idoko1, O Agbaji1, P Agaba1, L Akintunde1, M Muazu1, G Imade1, J L Sankale2, R Murphy2, and P Kanki2
1APIN Plus/Harvard PEPFAR, Jos Univ Teaching Hosp, Nigeria and 2Harvard Sch of Publ Hlth, Boston, MA, US |
| 614 |
A Statistical Model to Predict the Development of HIV Drug Resistance in Drug-naďve Individuals Incorporating the Effects of Boosted PI Regimens and Adherence
Vikram Gill*, P Harrigan, R Hogg, and V Lima
BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada |
615
|
Phenotypic Susceptibility in vitro to Amprenavir, Atazanavir, Darunavir, Lopinavir, and Tipranavir of HIV-2 Clinical Isolates from the French ANRS HIV-2 Cohort
D Desbois1, G Peytavin1, S Matheron1, F Damond1, G Collin1, A Bénard2, P Campa3, G Chęne2, F Brun-Vézinet1, Diane Descamps*1, and The French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
1Hosp Bichat-Claude Bernard, Paris, France; 2INSERM U593, Bordeaux, France; and 3Hosp St Antoine, Paris, France |
|
